XBiotech is a biopharmaceutical company that discovers and develops monoclonal antibody therapeutics. The company's platform focuses on true human monoclonal antibodies—antibodies derived directly from human donors rather than engineered—targeting inflammatory and infectious diseases. Its primary pipeline centers on interleukin-1 alpha (IL-1α) inhibitors, which the company is investigating across multiple therapeutic indications including cancer, stroke, myocardial infarction, arthritis, and conditions involving tissue breakdown, angiogenesis, thrombosis, and muscle wasting.
The company operates with a staff of 88 full-time employees and maintains operations from its headquarters in Austin, Texas. XBiotech was incorporated in 2005 and is listed on the Nasdaq. The company has a market capitalization of approximately $0.1 billion, reflecting a small-cap profile within the biotechnology sector. As a development-stage biopharmaceutical company, XBiotech's commercial activities remain limited, with revenue generation dependent on advancing its pipeline candidates through clinical development and potential regulatory approval.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.26 | $-1.26 | -55.6% | |
| 2023 | $-0.81 | $-0.15 | +25.0% | |
| 2022 | $-1.08 | $-0.10 | -86.2% | |
| 2021 | $-0.58 | $-0.58 | -61.1% | |
| 2020 | $-0.36 | $-0.36 | -102.4% | |
| 2019 | $14.82 | $16.67 | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-18 | 0001171843-25-001527 | SEC ↗ |
| 2023-12-31 | 2024-03-15 | 0001171843-24-001382 | SEC ↗ |
| 2022-12-31 | 2023-03-15 | 0001171843-23-001705 | SEC ↗ |
| 2021-12-31 | 2022-03-15 | 0001171843-22-001904 | SEC ↗ |
| 2020-12-31 | 2021-03-16 | 0001171843-21-001828 | SEC ↗ |
| 2019-12-31 | 2020-03-16 | 0001171843-20-001761 | SEC ↗ |
| 2018-12-31 | 2019-03-14 | 0001171843-19-001708 | SEC ↗ |
| 2017-12-31 | 2018-03-16 | 0001171843-18-002043 | SEC ↗ |
| 2016-12-31 | 2017-03-16 | 0001171843-17-001571 | SEC ↗ |
| 2015-12-31 | 2016-03-30 | 0001171843-16-008925 | SEC ↗ |